Purpose To describe the pharmacokinetics of orally administered ABT-751 and its conjugated metabolites in children with neuroblastoma and other solid tumors and to relate pharmacokinetic parameters to toxicity and therapeutic outcomes. Methods Patients (median age, 11 years) with neuroblastoma (n = 37) or other solid tumors (n = 25) had pharmacokinetic sampling after the Wrst dose of ABT-751 (75-250 mg/m 2 /day) on a 7-day or 21-day schedule. ABT-751 and its glucuronide and sulfate metabolites were quantiWed with an HPLC/MS/MS assay. Pharmacokinetic parameters were derived with non-compartmental methods. The relative bioavailability of more water soluble capsule and suspension formulations was assessed.
Introduction
ABT-751 (Abbott Laboratories, Abbott Park, IL) is an orally bioavailable sulfonamide that inhibits microtubule polymerization by binding to the colchicine binding site on -tubulin and preferentially to 3-tubulin [1, 2] . Phase 1 clinical trials evaluated 7-and 21-day schedules with once or twice daily oral administration [3] [4] [5] [6] . The recommended dose in adults on the 7-day schedule was 250 mg/day (equivalent to »140 mg/m concentration at 24 h was 0.5 mcg/ml. Inter-patient variability in pharmacokinetic parameters in adults was low. ABT-751 is eliminated by glucuronidation and sulfation, and these conjugated metabolites are measurable in plasma and urine. In adults, »50% of an orally administered dose is eliminated in urine as these conjugated metabolites [5] .
The phase 1 trial of ABT-751 in children with refractory solid tumors evaluated two schedules-daily for seven consecutive days every 21 days (7-day schedule) and daily for 21 consecutive days every 28 days (21-day schedule) [3, 4] . The maximum tolerated dose (MTD) was 200 mg/m 2 /day (equivalent to »360 mg/day in adults, based on BSA = 1.8 m 2 ) on the 7-day schedule and 100 mg/m 2 /day on the 21-day schedule. The 21-day schedule was poorly tolerated in children. Clinical development (phase 2) of ABT-751 in children is currently focused on neuroblastoma because pre-clinical in vitro and in vivo studies and the clinical experience on a phase 1 trial suggested selective activity in this tumor [3, 4, 7, 8] . The aim of this work was to perform pharmacokinetic studies in the children enrolled on this phase 1 trial and in children with relapsed neuroblastoma enrolled on a subsequent pilot study of 200 mg/m 2 /day on the 7-day schedule, compare the pharmacokinetics in children and adults, and correlate the pharmacokinetic parameters with toxicity and outcome in children.
Materials and methods

Patient population
Seventy-six patients were enrolled on our phase 1 trial of ABT-751 between May 2002 and April 2007 at the three participating sites (Pediatric Oncology Branch, NCI; Children's Hospital of Philadelphia; Children's Memorial Hospital, Chicago). The trial included dose-Wnding studies for the 7-and 21-day dosing schedules and a pilot study in children with neuroblastoma. The eligibility, design, and results of the dose-Wnding and pilot studies were previously reported [3, 4, 9] . The protocol was approved by the Institutional Review Boards of the participating institutions, and all patients or their parents consented to participation in the optional pharmacokinetic studies. Assent was obtained according to institutional guidelines.
Drug supply and administration ABT-751 was supplied by Abbott Laboratories as 25 and 100 mg capsules in two tautomeric forms (Form 1 and 2) and as a 25 mg/ml suspension (Form 2) for oral administration. The suspension formulation, which is taken up in puriWed or sterile water, contains Form 2 ABT-751 and sucrose, xanthan gum, colloidal silicon dioxide, and an orange Xavor. Pharmacokinetic studies were performed with the Wrst dose of ABT-751 administered orally after breakfast. Dose was normalized to body surface area and rounded to the nearest 25 mg. Dose levels for the 7-and 21-day schedules are listed in Table 1 . The 33 patients enrolled on the neuroblastoma pilot portion of the trial were treated on the 7-day schedule at a dose of 200 mg/m 2 /day. Plasma and urine pharmacokinetic sampling and drug assay Pharmacokinetic samples were collected after the Wrst dose on cycle 1. On the dose escalation portion of the trial on the 7-and 21-day schedules, 3 ml blood samples were collected in EDTA tubes immediately prior to the dose of ABT-751 and 0.5, 1, 2, 3, 5, 8, 10-12, and 24 h after the dose. Trough blood samples were also drawn prior to the 5th and 7th doses. Blood samples were placed immediately into ice, and plasma was separated by centrifugation in a pre-chilled centrifuge within 1 h and frozen at ¡20°C. A 24-h urine sample was collected after the Wrst dose when feasible. A less extensive sampling schedule was used in patients enrolled on the neuroblastoma pilot arm. Blood samples were drawn prior to the dose and 1, 3, 6, 10-12, and 24 post-dose with a single trough sample on day 5. This limited sampling schedule was also used to study the relative bioavailability of a more water soluble tautomer of ABT-751 (Form 2) in capsules and a suspension formulation of ABT-751. On day 1 and day 2 of cycle 1, two subsets of patients were studied after equal doses of either the two capsule forms (Form 1 vs. Form 2, n = 8) or capsules versus suspension (n = 6) with the order of administration randomly assigned. Patients on the Form 1 versus Form 2 study also had pharmacokinetic sampling performed on day 1 of cycle 2 with the alternate Form of the drug that was studied on day 1 of cycle 1 when feasible (n = 3). ABT-751 and its two conjugated metabolites were quantiWed in plasma and urine using a previously described HPLC tandem mass spectrometry assay [10] .
Pharmacokinetic and pharmacodynamic analyses
The ABT-751 and metabolite plasma concentration-time data were analyzed using non-compartmental methods. The peak concentration (C max ) and time to peak concentration (T max ) were determined from a concentration-time curve for each patient. Area under the concentration curve to the last measured time point (AUC 0-last ) was calculated with the linear trapezoidal method and extrapolated to inWnity (AUC 0-1 ) by adding the Wnal measured plasma concentration divided by the terminal rate constant, which was derived from the slope of the natural log-transformed concentrations and times on the terminal elimination phase of the decay curve. The day 2 AUC 0-1 on the Form 1 versus Form 2 and capsule versus suspension relative bioavailability studies were corrected for residual drug exposure from the day 1 dose by subtracting the concentration in the day 2 pre-dose sample divided by the day 1 terminal rate constant. The half-life (t 1/2 ) was calculated by dividing 0.693 by the terminal rate constant. Apparent clearance (CL/F) was calculated by dividing the dose by the AUC 0-1 , and the relationship between patient age and CL/F was assessed using Spearman correlation. Accumulation of ABT-751 over the 7-or 21-day dosing interval was estimated from the ratio of the AUC 0-1 , which equals the AUC 0-24 h at steady state, to the AUC 0-24 h after the Wrst dose. The average plasma concentration (C ave ) is the AUC 0-1 divided by the dosing interval (24 h). The ratio of the plasma AUC 0-1 for the glucuronide and sulfate metabolites and the fraction of the ABT-751 dose excreted in the urine over 24 h as the parent drug and metabolites were calculated after conversion to molar units. The relationship between patient age and glucuronide:sulfate molar ratio was assessed using Spearman correlation.
The AUC 0-1 in 16 patients who experienced a doselimiting toxicity (DLT) on the Wrst treatment cycle was compared to the AUC 0-1 in 45 patients who had tolerable toxicity during cycle 1 using the non-parametric MannWhitney test separately for the 7-and 21-day schedules.
Results
Patient characteristics
Sixty-two (82%) of the 76 patients enrolled on our pediatric phase 1 trial of ABT-751 participated in pharmacokinetic studies, including 39 (91%) of the 43 patients enrolled on the dose-Wnding portion of the trial for the 7-and 21-day schedules and 23 (70%) of the 33 enrolled on the neuroblastoma pilot portion. The median (range) age of the 62 patients was 11 years (2-18 years), and 40 were male and 22 were female. Thirty-seven patients had neuroblastoma (median age, 9 years), 18 had a sarcoma, and seven had other cancer types.
Pharmacokinetics of ABT-751
The plasma concentration-time proWles of ABT-751 and its metabolites are shown in Fig. 1 . ABT-751 was rapidly absorbed after an oral dose (median time to peak concentration, 2.1 h) and plasma concentration declined monoexponentially with a median half-life of 5.1 h. Pharmacokinetic parameters in the 62 patients studied at 6 dose levels are listed in Table 2 . Similar results were obtained using the two sampling schedules (Fig. 1) ; therefore, data generated from the detailed and limited sampling schedules are combined for most analyses.
The AUC 0-1 increased in proportion to the dose over the dosage range from 75 to 250 mg/m 2 ( Fig. 2a) . At the recommended dose for children of 200 mg/m 2 /day on the 7-day schedule, the median AUC 0-1 was 91 mcg h/ml, which is equivalent to a C ave in plasma of 3.9 mcg/ml (10 mcM). For an orally administered agent, the inter-patient variability of the parent drug pharmacokinetic parameters was low, as evidenced by the observation that the median deviation of the AUC 0-1 from the line of proportionality in Fig. 2a  was 19% .
The median (range) apparent clearance (CL/F) was 33 (16-120) ml/min/m 2 , and CL/F was similar in males (33 ml/min/m 2 ) and females (30 ml/min/m 2 ). CL/F did not appear to be age-dependent (Spearman correlation coeYcient, ¡0.09; Fig. 2b ), but the youngest patient, who was 2 years old, had a substantially higher CL/F of 120 m/min/m 2 , which was not a result of poor absorption because the glucuronide and the sulfate metabolite AUCs were similar to those of other patients treated at the same dose level. In addition, this patient was studied on two consecutive days as part of the Form 1 versus Form 2 study with identical results (AUC 0-1 of 29 mcg h/ml on both days). The glucuronide to sulfate plasma AUC 0-1 molar ratio in this patient was 0.78.
The mean ratio of AUC 0-1 :AUC 0-24 h after the Wrst dose was 1.06 § 0.08, indicating that the AUC 0-24 h at steady state would only be 6% higher than the AUC 0-24 h after the Wrst dose. Median trough (24 h post-dose) plasma concentrations on days 2, 5 and 7 were < 1 mcg/ml at all dose levels, and there was no evidence of signiWcant drug accumulation. At the 200 mg/m 2 /day dose level, median (range) trough concentrations were 0.47 (0.14-2.42) mcg/ml on day 2, 0.53 (0.03-3.27) mcg/ml on day 5 and 0.68 (0.24-0.69) mcg/ml on day 7. Therefore, accumulation of ABT-751 with once daily dosing is minimal.
The glucuronide and sulfate metabolites of ABT-751 were measurable in plasma 30 min after the dose and plasma concentration of the sulfate peaked at a median of 3 h post-dose and the glucuronide peaked at 5 h. The median molar AUC 0-1 ratio of glucuronide to sulfate metabolites in plasma was 0.57 (range, 0.24-1.6), and the sulfate metabolite AUC 0-1 exceeded the glucuronide metabolite AUC 0-1 in 56 of 62 patients. The median plasma AUC 0-1 s of the glucuronide and the sulfate metabolites were 98 and 160 mcg h/ml, respectively at the 200 mg/m 2 dose level. The glucuronide:sulfate AUC 0-1 molar ratio in plasma was not age-dependent (Spearman r = 0.10). The median (range) percentage of the dose excreted in the urine over 24 h after the Wrst dose in 28 patients was 0.05 (0-0.40%) for ABT-751, 10 (1.0-39%) for ABT-751 glucuronide, and 13 (2.3-51%) for ABT-751 sulfate. Relative bioavailability of form 2 and suspension
The bioavailability of the more water soluble tautomer of ABT-751 (Form 2) relative to Form 1 was studied in eight patients, and the results are listed in Table 3 . The mean relative bioavailability of Form 2 was 105%. The molar glucuronide:sulfate ratio was lower with Form 2 compared to Form 1 in all eight patients (p < 0.01) but only by a median of 12 (range, 1-21%), and the CL/Fs of Form 1 (median, 33 ml/min/m 2 ) and Form 2 (36 ml/min/m 2 ) were similar (p = 0.64).
The bioavailability of the suspension formulation was compared to capsules (Form 2) in 6 patients who received the two formulations on consecutive days in random order. The mean § SD relative bioavailability of the suspension was 93 § 17%.
The intra-patient variability in the 14 patients who were studied on two consecutive day in these relative bioavailability studies was minimal. The mean ( §SD) diVerence in the AUC 0-1 on days 1 and 2 was 14 § 6%.
Pharmacodynamic pharmacokinetic relationships
Dose-limiting toxicity (DLT) on cycle 1 occurred in 16 of 61 patients who underwent pharmacokinetic sampling (one patient on the 21-day schedule was not evaluable for toxicity). Dose-limiting toxicities included sensory and motor neuropathy, fatigue, hypertension, nausea, vomiting, dehydration, abdominal pain, and constipation [3, 4, 9] . The distribution of patients with a DLT by dose level is shown in Table 1 , and the relationship between ABT-751 AUC 0-1 and DLT is shown in Fig. 3 . On the 7-day schedule, patients who experienced DLT on cycle 1 had a signiWcantly higher AUC 0-1 (median, 120 mcg h/ml) than those with tolerable toxicity (median, 85 mcg h/ml). The incidence of cycle 1 DLT overall on the 7-day schedule was 10/ 46 (22%), but in patients with an AUC 0-1 > 100 mcg h/ml the incidence was 7/18 (39%) and with an AUC 0-1 >120 mcg h/ml 5/10 patients (50%) experienced a DLT.
Five of 37 patients with neuroblastoma receiveḑ 50 cycles of ABT-751 and had no evidence of disease progression. The median (range) AUC 0-1 in these 5 patients was 75 (43-180) mcg h/ml compared to 93 (29-160) mcg h/ml in the remaining 32 patients with shorter times to progression. Two patients with no evidence of disease progression for greater than 50 cycles experienced a DLT during cycle 1 (AUC 0-1 were 78 and 180 mcg h/ml). Both had an initial dose reduction of 30% and continued on protocol therapy. The patient with the highest AUC 0-1 (180 mcg h/ml) required a second dose reduction in subsequent cycles. 
Discussion
We studied the pharmacokinetics of ABT-751 and its conjugated metabolites over a dosage range of 75-250 mg/m 2 in a large group of children ranging in age from 2 to 18 years (6 children < 6 years, 27 children 6-11 years, 29 children 12-18 years). Except for the youngest patient (2 years), who had a CL/F that was 3.5-fold higher than the population mean, CL/F was not age-dependent. Our results were also comparable to the results from the trial of ABT-751 in adults. The mean AUC 0-24 h of ABT-751 in adults treated at a dose of 250 mg (»140 mg/m 2 ) was 61 mcg h/ml, [5] and the AUC 0-24 h in the 9 children (median age, 11 years) treated at the 130 mg/m 2 dose level was 62 mcg h/ml.
As in adult subjects, the sulfate conjugate was the predominant metabolite of ABT-751 in the plasma and urine. Renal excretion was not a route of elimination for the parent drug and on average <25% of the dose of ABT-751 was excreted in the urine as conjugated metabolites. Incomplete 24-h urine collections in these children could account for the variability seen in the fraction of the dose excreted in urine as metabolites (range, 2.3-51% for the sulfate metabolite) and for underestimation of the urinary excretion of the conjugated metabolites. In plasma, the combined molar AUC 0-1 s of the glucuronide (median, 180 mcM h at 200 mg/m 2 ) and the sulfate (350 mcM h) metabolites exceeded the molar AUC 0-1 of the parent drug (240 mcM h). These high plasma concentrations of the conjugated metabolites and their detection in plasma 30 min after the ABT-751 dose are suggestive that some pre-systemic (Wrst-pass) metabolism of ABT-751 is occurring after oral administration.
The relative bioavailability of the three dosing formulations used on this trial was equivalent. Although the number of patients who were studied on two consecutive days to compare Form 1 to Form 2 capsules (n = 8) and Form 2 capsules to Form 2 suspension (n = 6) was small, the intra-patient variability was low, and in most cases the diVerences between AUC 0-1 s of the two dosing forms being compared was <15%. Therefore, the formulations can be used interchangeably without adjusting the dose.
Seven of the 10 patients who experienced a dose-limiting toxicity from ABT-751 on the 7-day schedule had an ABT-751 AUC 0-1 > 100 mcg h/ml, and the incidence of DLT in the 18 patients with an AUC 0-1 > 100 mcg h/ml on this schedule was 39% compared to 11% in the 28 patients with an AUC 0-1 < 100 mc h/ml. Although eYcacy is diYcult to quantify on a phase 1 trial, Wve of the 37 patients with neuroblastoma survived progression-free for more than 3 years and the median AUC 0-1 in these 5 patients was 75 mcg h/ml, suggesting that a therapeutic eVect can be achieved with this drug at drug exposures (AUC 0-1 ) that are tolerable. At the recommended dose of ABT-751 for children (200 mg/m 2 /day for 7 days repeated every 21 days), the median AUC 0-1 was 91 mcg h/ml and 16 of the 29 patients had an AUC 0-1 < 100 mcg h/ml. This analysis may provide a basis for dose reductions and individualized dosing of ABT-751 in children.
ABT-751 has a number of favorable pharmacological characteristics. It is orally bioavailable, it has minimal inter-and intra-patient pharmacokinetic variability, the AUC is proportional to the administered dose so that dose modiWcations result in a predictable changes in drug exposure, and it is eliminated by conjugation to both glucuronide and sulfate conjugates, which minimizes the risk of drug interactions. An ongoing Phase 2 study of ABT-751 through the Children's Oncology Group is designed to determine whether this agent is active against refractory neuroblastoma. Fig. 3 Relationship between AUC 0-1 and dose-limiting toxicity (DLT) on the Wrst cycle of therapy on the two treatment schedules. The horizontal bars represent the median AUC 0-1 for each group. Twotailed P values were generated using the Mann-Whitney test
